LeadArt Biotechnologies automates chemoproteomics processes to accelerate drug discovery by integrating biotechnology and automation technologies. Its core offering is an automated chemoproteomics platform designed to discover disease-related targets and chemical probes, including for traditionally undruggable and unexplored targets. The company is developing a human live-cell target-probe database as a central resource for its discovery efforts. LeadArt intends to use the latest financing to advance development of its platform and to create the human target-probe database. The company recently signed a strategic collaboration with AstraZeneca’s iCampus to develop a herbal medicine preclinical translation platform in Chengdu, China. LeadArt is led by CEO Feng Ni and operates out of Boston, MA and Ningbo, China.

Total raised

$6M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2023